Health Care & Life Sciences » Biotechnology | GeneOneLifeScience Inc.

GeneOneLifeScience Inc. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
8,171
18,967
20,979
37,265
22,021
22,378
Total Accounts Receivable
4,488
4,064
6,965
7,296
4,828
7,199
Inventories
6,144
6,134
6,893
7,017
6,876
7,828
Other Current Assets
694
275
445
1,332
928
778
Total Current Assets
19,497
29,440
35,282
52,910
34,653
38,183
Net Property, Plant & Equipment
1,429
1,700
3,049
4,287
3,427
6,112
Total Investments and Advances
4,842
4,744
3,832
3,615
3,268
3,217
Long-Term Note Receivable
7
17
5
54
21
527
Intangible Assets
5,896
4,865
4,334
4,193
3,986
524
Other Assets
149
-
-
199
253
566
Total Assets
31,820
40,766
47,691
65,662
45,634
49,296
ST Debt & Current Portion LT Debt
2,706
816
1,165
22,069
1,456
Accounts Payable
897
835
844
1,702
2,291
Income Tax Payable
16
18
18
32
73
Other Current Liabilities
2,788
2,607
4,664
4,874
4,749
Total Current Liabilities
6,407
4,276
6,691
28,678
8,568
Provision for Risks & Charges
828
943
477
115
-
Deferred Taxes
-
14
1,183
403
18
Other Liabilities
875
801
1,078
1,017
517
Total Liabilities
8,110
6,035
8,252
29,809
9,094
Common Equity (Total)
23,711
34,731
39,439
35,852
36,540
Total Shareholders' Equity
23,711
34,731
39,439
35,852
36,540
Total Equity
23,711
34,731
39,439
35,852
36,540
Liabilities & Shareholders' Equity
31,820
40,766
47,691
65,662
45,634

About GeneOneLifeScience

View Profile
Address
Unit 1903, Keungil Tower
Seoul SL 06142
Korea, Republic Of
Employees -
Website http://www.genels.com
Updated 07/08/2019
GeneOne Life Science, Inc. engages in the research, development, and manufacture of deoxyribonucleic acid (DNA) vaccines for the prevention and treatment of diseases. Its products include VGX-3400, VGX-3500, and fluprime. Its service include process cost analysis, sterility testing, research batch production, strain selection, cell bank characterization, and others.